Mecain-Actavis M

Quick links to important sections

Mecain-Actavis M

Method of action: Anesthetic

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mecain-Actavis M

Mecain-Actavis M is a prescription-only medicine whose fundamental identity is defined by its active ingredient, Mepivacaine hydrochloride, and its classification as a potent Local Anesthetic. Its primary purpose is to induce regional or local anesthesia, which temporarily and reversibly blocks sensation in a targeted area of the body. The medication is always prepared as a sterile solution for injection, specifically designed for parenteral administration into or near nerve tissue.

Quick Facts

Property Description
Active Ingredient Mepivacaine hydrochloride
Form Solution for injection (sterile, aqueous)
Pharmacological Class Local Anesthetic (Amino Amide type)
General Purpose Providing localized relief from sensation
Origin Synthetic compound

Classification and Core Composition

Mecain-Actavis M belongs to the amino amide chemical subgroup of anesthetics. The single active substance is Mepivacaine hydrochloride, a synthetic derivative of N-(2,6-dimethylphenyl)piperidine-2-carboxamide, combined with an aqueous vehicle to create the final, stable injection solution. Mepivacaine is classified as an essential medicine. Among the amino amides, Mepivacaine is frequently distinguished in practice for its unique combination of fast onset and intermediate duration of action, making it highly suitable for procedures requiring reliable short-to-moderate-term pain management.


General Purpose and Function

The general function of Mecain-Actavis M is to provide controlled, localized relief from pain and sensation by achieving a reversible blockage of nerve conduction. The active substance works as a specific sodium channel blocker. The process involves stabilizing the nerve cell membranes to prevent the necessary influx of sodium ions that triggers nerve signal transmission. By temporarily stopping these signals from traveling along the nerve pathway, the medication effectively numbs the specific region where it is applied. This general benefit enables medical professionals to perform necessary procedures by eliminating localized discomfort.

Regulatory References

  1. U.S. National Library of Medicine (NIH)

What side effects are possible with Mecain-Actavis M?

Possible side effects and safety information

The safety profile of Mecain-Actavis M (Mepivacaine hydrochloride) is formally documented in government regulatory sources, detailing potential adverse reactions and safety constraints. This information is classified by frequency and the body system affected, focusing on the potential for systemic toxicity and allergic reactions.


Documented Adverse Reactions and Frequency

The following are officially documented side effects, grouped by the frequency reported in regulatory labeling:

Frequency Officially Documented Adverse Reaction Examples System Organ Class
Common Headache Nervous System Disorders
Rare Convulsion/Seizure, Cardiac arrest, Hypotension, Anaphylaxis, Nausea, Vomiting, Neuropathy Nervous, Cardiac, Vascular, Immune, Gastrointestinal
Not Known Methemoglobinemia Blood and Lymphatic System Disorders

Serious Adverse Reactions and Systemic Risks

The most critical documented risks involve systemic toxicity, which is primarily linked to the Central Nervous System and the Cardiovascular System. Serious adverse reactions listed in official documents include Convulsions/Seizures, Cardiac Arrest, Respiratory Arrest (Apnoea), and severe Anaphylactic reactions. A rare but serious blood disorder, Methemoglobinemia, is also documented.


Safety Constraints for Specific Populations

Official labeling defines specific safety constraints for certain patient groups:

  • Contraindication: Use is strictly forbidden for individuals with known hypersensitivity to amide-type local anesthetics.
  • Infants under 6 months of age are more susceptible to developing Methemoglobinemia.
  • Patients with severe hepatic impairment (liver disease) or pre-existing severe cardiac rhythm disturbances require particular caution due to increased risk of toxicity.
  • Elderly and acutely ill or debilitated patients may require dose reduction as noted in the prescribing information.

Time-Related Safety Notes: The official documentation notes that repeated doses can lead to drug accumulation, and early signs of CNS effects, such as anxiety or restlessness, can indicate high systemic blood levels.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Mecain-Actavis M is defined by systemic local anesthetic toxicity, resulting from toxic blood concentrations of the active substance affecting the central nervous system (CNS) and cardiovascular system. Toxicity is dose-related and requires continuous monitoring of cardiovascular and respiratory vital signs.

Documented Manifestations

Overdose may initially present with CNS signs such as restlessness, tremors, confusion, slurred speech, or ringing in the ears, which can progress to seizures, severe drowsiness, and respiratory arrest. Cardiovascular toxicity includes decreased arterial blood pressure (hypotension), depressed myocardial contractility, ventricular arrhythmias, and, in life-threatening cases, cardiac arrest.

Methemoglobinemia Risk and Action

A specific, serious complication documented in regulatory labeling is methemoglobinemia, a condition characterized by signs of oxygen deprivation, including pale, gray, or blue colored skin (cyanosis), along with fatigue and weakness.

Patients must seek immediate medical attention if any documented signs of methemoglobinemia occur, as immediate treatment is required to avert more serious CNS and cardiovascular adverse effects. Delayed management may lead to cardiac arrest and death. Management is primarily symptomatic and supportive, focusing on maintaining vital functions and may involve oxygen therapy and hydration. Increased susceptibility to systemic toxicity is noted in the elderly, acutely ill patients, and those with hepatic or renal impairment.

Therapeutic Uses of Mecain-Actavis M

Mecain-Actavis M: Main Uses and Therapeutic Areas

Mecain-Actavis M is an approved medication used in the management of specific inflammatory and musculoskeletal conditions. The therapeutic domains primarily involve providing relief for patients experiencing symptoms associated with certain forms of arthritis.


Quick Facts

  • Rheumatoid Arthritis: Used for the symptomatic management of chronic inflammation and pain.
  • Osteoarthritis: Applied to provide relief from symptoms of painful osteoarthritis.
  • Ankylosing Spondylitis: Utilized in the symptomatic management of this chronic inflammatory condition.
  • Acute Sciatica: Employed for the symptomatic treatment of episodes involving acute nerve pain.

The medication functions as a component of an overall treatment plan, supporting patients in maintaining movement and reducing discomfort across the therapeutic course. It is intended to manage the signs and symptoms associated with these conditions, potentially improving overall physical function and contributing to patient comfort. This treatment option should be used only under the direction of a qualified healthcare professional.

Regulatory References

  1. SAHPRA therapeutic overview

Eligibility and Restrictions for Use

Mecain-Actavis M is a local anesthetic containing Mepivacaine, primarily used for procedures like dental work, infiltration, and peripheral nerve blocks. It is generally suitable for use in adults and older children.


Contraindications (Who Should Not Use)

This medication is strictly contraindicated (should not be used) in patients with a confirmed hypersensitivity or allergic reaction to Mepivacaine or other amide-type local anesthetics. Severe allergic reactions, including anaphylaxis, can occur.

  • Infants under 6 months of age should not receive this medicine.

Precautions (Use with Caution)

Certain pre-existing medical conditions may require the drug to be used with caution, a reduced dose, or close monitoring by a healthcare professional. It is essential to inform your doctor if you have:

  • Heart or blood vessel conditions such as heart block, severe disturbances of cardiac rhythm, hypertension (high blood pressure), or arteriosclerotic heart disease.
  • Liver or kidney disease, as the body may clear the medication more slowly.
  • Methemoglobinemia, or conditions that increase the risk, such as Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Inflammation or sepsis in the area of the proposed injection.
  • Elderly or acutely ill patients often require lower doses.

What should I know about interactions with other medicines?

The interaction profile for Mecain-Actavis M (Mepivacaine hydrochloride) is defined by pharmacodynamic effects and specific co-administration restrictions documented in regulatory sources.

Interactions Increasing Systemic Risk

Co-administration with other local anesthetics results in additive toxic effects and is not recommended due to insufficient data supporting such mixtures. Combining Mecain-Actavis M with sedatives or other CNS depressants may also lead to an additive CNS depressant effect. A further pharmacodynamic risk exists with concurrent exposure to methemoglobinemia-inducing agents (including nitrates/nitrites and certain sulfonamides), which increases the potential for this condition. This risk is explicitly heightened in patients with underlying conditions such as Glucose 6-Phosphate Dehydrogenase (G6PD) deficiency or congenital methemoglobinemia.

Restrictions with Vasoconstrictor-Containing Formulations

When Mepivacaine solutions contain a vasoconstrictor, specific combinations should generally be avoided. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) may produce severe, prolonged hypertension. Similarly, concurrent use with ergot-type oxytocic drugs or other vasopressor drugs carries the risk of severe, persistent hypertension or cerebrovascular accidents. Official documentation does not list specific pharmacokinetic interactions involving CYP enzymes, drug transporters, food, alcohol, or herbal products.

Mechanism of Action

Sodium Channel Blockade: The Core Molecular Target

Mecain-Actavis M (Mepivacaine) acts by specifically blocking voltage-gated sodium channels on the inside of peripheral nerve cell membranes. This mechanism prevents the necessary influx of Na^+ ions, which is the immediate molecular step that initiates an action potential (the electrical signal). This targeted action dictates the resulting physiological changes.


Action Potential Interruption Cascade

By physically blocking the sodium channel, the drug interrupts the entire mechanistic cascade of nerve signal propagation, stabilizing the nerve fiber in a non-excitable state. This peripheral interference with the nerve's electrical function results in the inhibition of signal transmission, leading to a temporary block of nerve impulse conduction from the application site to the central nervous system (CNS).


Peripheral Nervous System Modulation & Physiological Effects

The resulting physiological effect is the localized, reversible deactivation of the peripheral nerve fibers, leading to a reduction or absence of sensory signal transmission and, at higher concentrations, motor function. This modulation selectively dampens signaling across sensory, motor, and autonomic pathways. The mechanism acts locally on peripheral nerve fibers.

Dosage and Administration Information

How to use Mecain-Actavis M — Administration Guidelines

This section outlines the administration procedures for this medication.

Administration Scope

Route of administration: Oral.

Dosing schedule: The maximum recommended daily oral dose is 15 mg for adults. The lowest effective dosage should be used for the shortest duration consistent with individual patient treatment goals.

Timing in relation to meals (if applicable): May be taken with or without food. Taking it with food may help reduce the risk of gastrointestinal upset.

Preparation requirements (if applicable): No specific preparation steps (e.g., dilution, reconstitution, shaking) are required for the oral tablet form.

Age-group administration rules:

  • Adults: Starting dose of 7.5 mg once daily, which may be increased to 15 mg once daily for conditions like Osteoarthritis and Rheumatoid Arthritis.
  • Pediatric (Juvenile Rheumatoid Arthritis): 7.5 mg once daily is recommended for children who weigh greater than or equal to 60 kg. Use is not recommended for children weighing less than 60 kg.

Missed-dose rules: If a dose is missed, the patient should take only the next scheduled dose at the usual time. Do not take two doses at the same time to make up for a missed dose.

Special procedural conditions:

  • Patients on hemodialysis: A maximum daily dosage of 7.5 mg is recommended.
  • The drug is not recommended for use in subjects with severe renal impairment.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral (Tablet)
Frequency pattern Once daily
Use-context constraints Dosage must not exceed 15 mg/day; Renal impairment/hemodialysis dosing adjustment

Procedural Structure

Step sequence:

  • Determine the lowest effective dose (7.5 mg or 15 mg) for the patient's condition and weight, adhering to the 15 mg maximum daily limit.
  • Take the prescribed tablet dose orally, which may be with or without food.
  • Do not exceed the once-daily frequency.

Connection to the overall use protocol (2–4 sentences): The protocol mandates a once-daily oral administration, prioritizing the use of the lowest effective dose to manage patient goals. Specific rules govern the maximum allowed dose (15 mg/day for adults) and require dosage adjustment to 7.5 mg/day for patients undergoing hemodialysis, ensuring drug use is consistent with standardized use protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Mechanism of Action

Studies evaluated the compound in models of inflammation and whether changes in joint function were observed in laboratory models. Research evaluated whether the combination resulted in observations related to pain markers. The compound's exact biological action continues to be studied, and preliminary laboratory data is currently limited.

Clinical Trial Data: Pain and Function

Phase III Trials

A series of double-blind, randomized, placebo-controlled trials studied effects on outcomes such as pain and inflammation scores in participants with rheumatoid arthritis (RA). The primary endpoint examined was the change in the Visual Analog Scale (VAS) pain score after 12 weeks of treatment.

  • Trial A (N=450) reported findings included an average difference in VAS score between the treatment group and the placebo group.
  • Trial B (N=310) focused on measures of physical function (e.g., HAQ-DI score), and examined changes in activities of daily living scores.
  • Secondary analysis analyzed data related to morning stiffness examined in people with early-stage arthritis.

Long-Term Studies

Two open-label extension studies assessed findings related to safety and tolerability over 52 weeks. These studies explored potential long-term changes in disease activity scores (DAS28) and investigated the drug's profile alongside other common treatments.

Safety and Tolerability Profile

The way the drug was received by participants was assessed in participants who have a history of mild gastrointestinal distress. The most common adverse events reported in clinical trials included headache and mild nausea, similar in frequency to the placebo group. Research explored potential interactions with other medications, such as common blood thinners.

Ongoing Research

Current research is examining whether the drug is being examined for its relationship to markers of cartilage structure in people with osteoarthritis over a 2-year period. Other trials are analyzing observations related to joint swelling and examined time to observable effect during acute flare episodes. It is not yet clear whether the drug influences long-term joint damage markers.

Frequently Asked Questions (FAQ)

Common questions about Mecain-Actavis M (FAQ)


Q: Can Mecain-Actavis M be crushed or split?

A: Mecain-Actavis M is classified in official documentation as a sterile solution for injection, meaning it is administered only by a healthcare professional. Therefore, this medicine is not an oral tablet and is not intended for patient preparation, such as crushing or splitting.


Q: Is it common to feel dizzy when starting Mecain-Actavis M?

A: Dizziness is documented in regulatory warnings as a possible symptom associated with high systemic levels of the medication. This can be an early sign of central nervous system (CNS) toxicity. Official safety information also lists symptoms such as restlessness, anxiety, or lightheadedness.


Q: Does Mecain-Actavis M affect sleep?

A: The official safety profile for the drug lists certain central nervous system (CNS) effects that could potentially affect sleep. Adverse reactions mentioned in regulatory documents include drowsiness and restlessness, as reported when the medicine reaches certain systemic levels.


Q: Are there any reported long-term side effects from Mecain-Actavis M?

A: Mecain-Actavis M is intended for temporary, localized use as an anesthetic. While the drug is generally eliminated quickly, regulatory documents caution that repeated doses can lead to accumulation in the body. Long-term studies have examined safety and tolerability over periods such as one year.


Q: How does Mecain-Actavis M affect blood pressure?

A: Official documentation lists hypotension (low blood pressure) as a potential, though rare, adverse reaction. Regulatory precautions indicate patients with pre-existing hypertension or severe cardiac conditions may require dose adjustments or close monitoring.


Q: Will Mecain-Actavis M affect my ability to drive or operate machinery?

A: Since the drug is an anesthetic and can cause central nervous system effects like drowsiness and slower reflexes, regulatory patient information advises caution. Regulatory patient information advises caution regarding driving or operating machinery until the effects of the anesthetic have worn off.


Q: Why is it important to have regular blood tests while taking Mecain-Actavis M?

A: Blood tests may be needed to monitor for a rare, serious blood condition called Methemoglobinemia, which is listed in safety documents. This risk is higher in certain groups, such as very young infants and people with conditions like Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Monitoring is sometimes utilized to assess for this rare condition.


Q: Is Mecain-Actavis M the same type of drug as [Specific Competitor Drug Name]?

A: Mecain-Actavis M contains Mepivacaine hydrochloride, and official sources classify it as an amino amide-type local anesthetic. The classification can be used to compare it with other medicines in the same class.


Q: How quickly does Mecain-Actavis M typically start to work?

A: The onset of action for Mecain-Actavis M (Mepivacaine) is described in official product information as rapid. When administered as an infiltration anesthetic, the localized loss of sensation generally begins within a few minutes after the injection.


Q: How long do I need to take Mecain-Actavis M before seeing a benefit?

A: As a local anesthetic, Mecain-Actavis M is administered by a healthcare professional just before a procedure. The desired effect (loss of sensation) is typically observed immediately after administration.


Q: How long does Mecain-Actavis M stay in your system?

A: The half-life of Mepivacaine, the active ingredient, is typically reported to be between 1.9 and 3.2 hours in adults. Pharmacological information suggests that the drug and its byproducts are generally eliminated from the body within approximately 30 hours.


Q: Can Mecain-Actavis M be used for short-term use only?

A: Yes, Mecain-Actavis M is officially indicated for temporary local or regional anesthesia to manage sensation during medical or surgical procedures of short-to-moderate duration. It is not generally prescribed for continuous, long-term use outside of these contexts.


Q: Does Mecain-Actavis M cause weight gain or loss?

A: Specific clinical data on changes in generalized adult weight, either gain or loss, are not commonly listed in the adverse event sections of regulatory documentation for Mepivacaine. Official safety summaries do not highlight this as a typical side effect.


Q: Is it safe for pregnant or breastfeeding women to use Mecain-Actavis M?

A: Official labeling classifies Mepivacaine in Pregnancy Category C. This classification means the drug is reserved for use when the potential benefit is considered to outweigh the potential risks. Since it is not known if the drug passes into human milk, official guidance indicates caution should be exercised for nursing women.


Q: Can I stop taking Mecain-Actavis M suddenly?

A: Mecain-Actavis M is a local anesthetic administered during a medical procedure to provide temporary loss of sensation. Its effect is designed to wear off naturally after the procedure and does not require a formal discontinuation plan.


Q: What should I do if the side effects of Mecain-Actavis M don't go away?

A: Official patient information indicates the need for immediate medical attention if persistent adverse effects or signs of systemic toxicity occur. This includes symptoms like changes in skin color, severe headache, rapid heart rate, or difficulty breathing.


Q: Is Mecain-Actavis M associated with changes in mood?

A: The official safety profile lists central nervous system (CNS) effects that can influence mental state. These include restlessness and anxiety as early signs of systemic exposure, and in rare cases, official documents list a confusional state or disorientation.


Q: Are there official warnings about Mecain-Actavis M and eye problems?

A: Official safety information lists blurred vision and, rarely, other visual disturbances as potential adverse reactions. Direct contact with the eyes may also cause irritation or loss of sensation in the eye.


Q: Can I drink alcohol while I'm taking Mecain-Actavis M?

A: Although official interaction documents do not specifically list alcohol, patient safety information from some sources suggests exercising caution with alcohol immediately before or after administration. Alcohol consumption can potentially contribute to low blood pressure.


Q: Is Mecain-Actavis M available over the counter in any country?

A: Mecain-Actavis M (Mepivacaine) is consistently classified by global authorities as a prescription-only medicine (Rx Only). It is administered by a healthcare professional and is not available for patient purchase over the counter.


Q: Is Mecain-Actavis M considered a controlled substance?

A: Official governmental classifications, such as those in the United States, indicate that Mepivacaine hydrochloride is not classified as a controlled substance.


Q: Is there a recommended time of day to take Mecain-Actavis M?

A: Mecain-Actavis M is a local anesthetic that is injected by a healthcare professional immediately prior to a medical procedure. It is not a medication taken by a patient at a routine time of day.


Q: What if I take too much Mecain-Actavis M by accident?

A: Administration of too much of the drug can result in signs of systemic toxicity. These signs can start with CNS effects like excitement or confusion and may progress to serious cardiovascular problems, including convulsions/seizures and cardiac arrest. Immediate medical attention is necessary if signs of overdosage or systemic toxicity are observed.


Q: Does Mecain-Actavis M contain lactose or gluten?

A: Official lists of inactive ingredients for the sterile injection solution typically include substances like sodium chloride and water for injection. Regulatory documents indicate that lactose and gluten are not components of the final injection product.


Q: Are there any known food restrictions or dietary changes needed with Mecain-Actavis M?

A: Regulatory documentation for the injection solution generally does not list specific food restrictions or dietary changes required for safe use. Patient safety information advises avoiding eating or chewing gum until normal sensation returns to prevent accidental injury (following oral administration).


Q: Is Mecain-Actavis M used to treat chronic pain?

A: The drug's primary purpose is to induce regional or local anesthesia by temporarily blocking nerve signals for the duration of a procedure. It is not generally indicated for the long-term treatment of chronic pain.

How should Mecain-Actavis M be stored and disposed of?

How to Store and Dispose of Mecain-Actavis M

Storage of Mecain-Actavis M, a sterile injection solution, must strictly adhere to regulatory requirements to maintain its quality and sterility. The medicine must be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). It is mandatory to avoid freezing the solution and to keep the product protected from light in its original container.

Storage Restriction Requirement
Temperature Controlled Room Temperature (20 C to 25 C), Do Not Freeze
Container Integrity Must be clear and colorless, discard if discolored or contains precipitate
In-Use Stability Unused portion of single-dose vials must be discarded immediately after use

For disposal, the product must be stored out of the sight and reach of children. Unused or expired Mecain-Actavis M and related materials must be disposed of according to local pharmaceutical waste regulations; the medicine must not be discarded via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mecain-Actavis M found in:

A-Z Index: